Drug Trial Radar · NCT07392957
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Jun 16, 2026
Primary completion
Jun 30, 2029
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Compass Therapeutics
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or in combination with CTX-471 will lead to enhanced tumor control and prolongation of overall survival of patients with recurrent glioblastoma. CTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and resistance mechanisms to bevacizumab, CTX-471 restores local immune reactivity through activation of costimulatory immune mediators. Combination of these two agents may further impair tumor proliferation through synergistic effects on the tumor microenvironment
Conditions
- Glioblastoma
Interventions
CTX-009Drug
CTX-009 will be given intravenously over the course of 60 minutes (+/- 5 minutes) on an outpatient basis every 2 weeks of a 28-day cycle.
CTX-471Drug
CTX-471 will be given intravenously over the course of 30 minutes (-5/+10) on an outpatient basis every 2 weeks of a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase IB Arm 1: Toxicity as measured by number of participants with adverse eventsTime frame: Start of treatment through 60 days after treatment (estimated to be 14 months)
- Phase IB Arm 1: Recommended Phase 2 Dose (RP2D)Time frame: Start of treatment through completion of cycle 1 (each cycle is 28 days)
- Phase IB Arm 2: Toxicity as measured by number of participants with adverse eventsTime frame: Start of treatment through 60 days after treatment (estimated to be 14 months)
- Phase II Arm 1: Overall survival rate at 12 months (OS12)Time frame: 12 months
- Phase II Arm 2: Overall survival rate at 12 months (OS12)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.